Karolina Kilowski, DO
Gynecologic Oncology · The Woodlands, TXNPI 1649659145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 25.3% of the total. 2025 is the largest year on record at $999, 4.3 times the $230 reported in 2019. That places this record below the midpoint for gynecologic oncology clinicians in TX, where the typical reported total is $3,034.
Across 46 payments — averaging $66.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$773
- Tempus AI, Inc$295
- Myriad Genetic Laboratories, Inc.$292
- Dilon Technologies, Inc.$193
- Integra Lifesciences Corporation$168
- AbbVie$141
- plus $1K from 15 others
Across 1 payment — averaging $35,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$35K
What the payments were for
- Food & beverage$2,95197%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $773 |
| Tempus AI, Inc | 6 | $295 |
| Myriad Genetic Laboratories, Inc. | 4 | $292 |
| Dilon Technologies, Inc. | 2 | $193 |
| Integra Lifesciences Corporation | 2 | $168 |
| AbbVie | 2 | $141 |
| Johnson & Johnson | 2 | $138 |
| Bayer | 1 | $125 |
| Biom'up France SAS | 1 | $110 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $105 |
| Seagen Inc. | 1 | $100 |
| GSK | 3 | $97 |
| Pacira Pharmaceuticals Incorporated | 2 | $96 |
| Merck | 1 | $95 |
| Davol Inc. | 1 | $93 |
| Eisai Inc. | 2 | $60 |
| Aadi Bioscience, Inc. | 1 | $58 |
| Genmab U.S., Inc. | 2 | $42 |
| Medical Device Business Services, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Mimedx Group, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$452
- HemoBlast Bellows$284
- Vitrakvi$125
- Elahere$125
- XT CDX$123
- myRisk$118
- Echelon Powered Circular$116
- BIOFIX$110
- BIODRESTORE$110
- BIODFACTOR$110
- BIODOPTIX$110
- MEDIHONEY$110
- Xerava$105
How this compares
$3,051 in reported general payments places this provider in the 50th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 40 | $920 |
| Gabapentin | 34 | $389 |
| Olanzapine | 27 | $130 |
| Ondansetron Hcl | 13 | $102 |
| Metoclopramide Hcl | 18 | $20 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in The Woodlands
- Richard DrakeThe Woodlands$25K
- Behrouz ZandThe Woodlands$10K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.